Literature DB >> 29074347

Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC.
METHODS: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention.
RESULTS: The consensus statements were discussed, debated and got consensus in each expert team. And then the statements were sent to all of the experts for further discussion and refinement. Finally, all of the experts were invited to vote for the statements, including the level of evidence and recommendation.
CONCLUSION: With the development of the management consensus guideline, HCC patients could benefit from the optimal therapeutic modality.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Diagnosis; Hepatocellular carcinoma; Staging; Surveillance; Treatment

Mesh:

Year:  2017        PMID: 29074347     DOI: 10.1016/j.jfma.2017.09.007

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  26 in total

1.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-18       Impact factor: 11.740

2.  The Role of Protease-Activated Receptor 2 in Hepatocellular Carcinoma after Hepatectomy.

Authors:  Ming-Chao Tsai; Chih-Che Lin; Ding-Wei Chen; Yueh-Wei Liu; Yi-Ju Wu; Yi-Hao Yen; Pao-Yuan Huang; Chih-Chien Yao; Ching-Hui Chuang; Chang-Chun Hsiao
Journal:  Medicina (Kaunas)       Date:  2021-06-04       Impact factor: 2.430

Review 3.  New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Int J Clin Oncol       Date:  2022-05-08       Impact factor: 3.850

4.  Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development.

Authors:  Chih-Tien Chen; Hsiang-Lin Lee; Hui-Ling Chiou; Chia-Hsuan Chou; Po-Hui Wang; Shun-Fa Yang; Ying-Erh Chou
Journal:  PLoS One       Date:  2018-06-11       Impact factor: 3.240

5.  Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.

Authors:  Nikhil Chauhan; Janet Bukovcan; Eveline Boucher; David Cosgrove; Julien Edeline; Bonnie Hamilton; Laura Kulik; Fayaz Master; Riad Salem
Journal:  JMIR Res Protoc       Date:  2018-08-15

6.  Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients.

Authors:  Rong-Yun Mai; Yan-Yan Wang; Tao Bai; Jie Chen; Bang-de Xiang; Guo-Bin Wu; Fei-Xiang Wu; Le-Qun Li; Jia-Zhou Ye
Journal:  Cancer Manag Res       Date:  2019-10-02       Impact factor: 3.989

7.  Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma.

Authors:  Pojen Hsiao; Kun-Chou Hsieh; Yaw-Sen Chen; Chia-Chang Hsu; Gin-Ho Lo; Yu-Chan Li; Pei-Min Hsieh; Hung-Yu Lin; Tsung-Chin Wu; Jen-Hao Yeh; Chih-Wen Lin
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 8.  Role of modern radiotherapy in managing patients with hepatocellular carcinoma.

Authors:  Liang-Cheng Chen; Hon-Yi Lin; Shih-Kai Hung; Wen-Yen Chiou; Moon-Sing Lee
Journal:  World J Gastroenterol       Date:  2021-05-28       Impact factor: 5.742

9.  Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Yao-Kuang Huang; Chieh-Ling Yen; Sz-Iuan Shiu; Shou-Wu Lee; Pi-Yi Chang; Hong-Zen Yeh; Teng-Yu Lee
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

10.  Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan.

Authors:  Shih-Chiang Kuo; Chia-Ni Lin; Yih-Jyh Lin; Wei-Ying Chen; Jing-Shiang Hwang; Jung-Der Wang
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.